There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tandem Diabetes Care (TNDM – Research Report), Aclaris Therapeutics (ACRS – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments.
Tandem Diabetes Care (TNDM)
In a report released yesterday, Matthew Taylor from Jefferies maintained a Buy rating on Tandem Diabetes Care, with a price target of $60.00. The company’s shares closed last Tuesday at $42.53, close to its 52-week low of $33.52.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of
Currently, the analyst consensus on Tandem Diabetes Care is a Moderate Buy with an average price target of $55.40.
See today’s best-performing stocks on TipRanks >>
Aclaris Therapeutics (ACRS)
In a report released yesterday, Roger Song from Jefferies maintained a Buy rating on Aclaris Therapeutics, with a price target of $32.00. The company’s shares closed last Tuesday at $8.14.
According to TipRanks.com, Song is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Aclaris Therapeutics is a Strong Buy with an average price target of $29.00, a 249.8% upside from current levels. In a report issued on March 6, SVB Securities also maintained a Buy rating on the stock.
Cogent Biosciences (COGT)
In a report released yesterday, Eun Yang from Jefferies maintained a Buy rating on Cogent Biosciences, with a price target of $18.00. The company’s shares closed last Tuesday at $12.98.
According to TipRanks.com, Yang is a 4-star analyst with an average return of
Currently, the analyst consensus on Cogent Biosciences is a Strong Buy with an average price target of $23.00, representing an 87.9% upside. In a report issued on February 27, SVB Securities also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TNDM:
- Tandem pairing with Abbott sensors can be ‘big deal,’ says Lake Street
- 3 Stocks to Buy Today, 2/24/2023, According to Top Analysts
- Tandem Diabetes price target lowered to $74 from $80 at Craig-Hallum
- Tandem Diabetes price target lowered to $50 from $70 at Piper Sandler
- Tandem Diabetes price target lowered to $52 from $61 at Cowen
